Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Levocarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.83 |
| ▸ | CPT2 | P23786 | 2/20 | 0.53 |
| ▸ | CPT1A | P50416 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | CRAT | P43155 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carnitine SCHEMBL3680647 | 1.00 | SLC22A16 (0.83) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL5712407 | 0.94 | SLC22A16 (0.80) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL5082345 | 0.94 | SLC22A16 (0.80) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL21970 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL3902633 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL21971 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL1813524 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| D-Carnitine SCHEMBL94286 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL17629811 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL4593172 | 0.91 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | claimed |
| US-20230346735-A1 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | LONZA GREENWOOD LLC | 2023-11-02 | — | — | US | claimed |
| CN-115317398-B | Ionic liquid collagen preparation and preparation method and application thereof | 广州樊文花化妆品有限公司 | 2023-09-19 | — | — | CN | claimed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | claimed |
| EP-4125858-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | Lonza Consumer Health Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| CN-115317398-A | Ionic liquid collagen preparation and preparation method and application thereof | 广州樊文花化妆品有限公司 | 2022-11-11 | — | — | CN | claimed |
| WO-2021221741-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | LONZA CONSUMER HEALTH INC. (US) | 2021-11-04 | — | — | WO | claimed |
| CN-113387836-A | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2021-09-14 | — | — | CN | claimed |
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2021-06-24 | — | — | US | claimed |
| EP-3164125-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | Nan Global, LLC (US) | 2017-05-10 | — | — | EP | claimed |
| EP-1218001-B1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2008-12-31 | — | — | EP | claimed |
| CN-101120935-A | Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2008-02-13 | — | — | CN | claimed |
| US-7303765-B2 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2007-12-04 | — | — | US | claimed |
| US-20050124558-A1 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2005-06-09 | — | — | US | claimed |
| EP-1218001-A4 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2005-05-18 | — | — | EP | claimed |
| CN-1399549-A | Ultra-fine L-carnitine, methods of making, compositions containing, and methods of using | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2003-02-26 | — | — | CN | claimed |
| US-20020111383-A1 | Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-08-15 | — | — | US | claimed |
| EP-1218001-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Sigma-Tau Healthscience S.p.A. (IT) | 2002-07-03 | — | — | EP | claimed |
| WO-2001017525-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA-TAU HEALTHSCUIENCE S.P.A (IT) | 2001-03-15 | — | — | WO | claimed |
| US-4602039-A | HYDROPHOPIC;BIOLOGICAL INJECTIONS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1986-07-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | SLC22A16 1032/4885CPT2 3/4885CPT1A 16/4885 |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | SLC22A16 1032/4885CPT2 3/4885CPT1A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.